Disc Medicine’s (IRON) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research note released on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $170.00 price target on the stock.

A number of other research analysts have also weighed in on the stock. Guggenheim began coverage on shares of Disc Medicine in a research note on Monday, November 9th. They issued a “buy” rating and a $132.00 price target on the stock. Wedbush increased their price objective on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. HC Wainwright increased their price objective on shares of Disc Medicine from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Wells Fargo & Company raised their price objective on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.27.

Get Our Latest Report on IRON

Disc Medicine Trading Down 1.3%

NASDAQ:IRON opened at $75.14 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 20.30. The business’s 50-day simple moving average is $71.71 and its 200-day simple moving average is $71.00. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The stock has a market capitalization of $3.42 billion, a PE ratio of -11.85 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.10. Sell-side analysts expect that Disc Medicine will post -6.18 earnings per share for the current fiscal year.

Insider Transactions at Disc Medicine

In related news, insider William Savage sold 16,035 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the completion of the transaction, the insider directly owned 63,445 shares in the company, valued at approximately $5,398,535.05. This trade represents a 20.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the sale, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 150,277 shares of company stock valued at $11,877,059 over the last three months. Company insiders own 3.76% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Disc Medicine in the second quarter valued at approximately $180,502,000. Assenagon Asset Management S.A. boosted its holdings in Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after purchasing an additional 735,300 shares during the last quarter. Opaleye Management Inc. boosted its holdings in Disc Medicine by 103.1% during the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after purchasing an additional 434,000 shares during the last quarter. Palo Alto Investors LP acquired a new position in Disc Medicine during the second quarter worth $30,473,488. Finally, Octagon Capital Advisors LP bought a new position in Disc Medicine in the first quarter valued at $17,264,000. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.